A Single-Center, Open-Label, Observer-Masked, Active-Controlled, Phase 2 Study of the Safety, Efficacy and Pharmacokinetics of EYN-1601 in Dilation of the Pupil

Trial Profile

A Single-Center, Open-Label, Observer-Masked, Active-Controlled, Phase 2 Study of the Safety, Efficacy and Pharmacokinetics of EYN-1601 in Dilation of the Pupil

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Phenylephrine (Primary)
  • Indications Eye disorders
  • Focus Therapeutic Use
  • Acronyms EYE 102
  • Sponsors Eyenovia
  • Most Recent Events

    • 30 Oct 2017 Primary endpoint (Pupil dilation) has been met, according to an Eyenovia media release.
    • 30 Oct 2017 According to an Eyenovia media release, results from this trial have been published in Therapeutic Delivery.
    • 30 Oct 2017 Results presented in an Eyenovia media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top